Quantcast
Last updated on April 17, 2014 at 17:30 EDT

Today’s Research on Mylan and Watson Pharmaceuticals: One Drug Maker’s Sorrow is Another One’s Joy

January 18, 2013

LONDON, January 18, 2013 /PRNewswire/ –

The patent cliff has seen many drug majors lose their exclusivity on blockbuster drugs
to generic makers in the past years and this trend is expected to go for some years to
come. In 2012 alone, over 40 branded drugs with a $35 billion yearly sales tag have lost
patent protection. StockCall has technical coverage on two of the biggest generic makers,
Mylan Inc. (NASDAQ: MYL) and Watson Pharmaceuticals Inc. (NYSE: WPI), which is available
for free upon registration at http://www.stockcall.com/report

The generic drug industry has been feasting on patent expirations in recent years, and
if the start of 2013 is anything to go on, this year could see more of the same. Major
branded drug companies have lost exclusivity rights to a number of top selling products,
and generic alternatives, as well as customer’s pockets, have been the main beneficiaries.

Mylan only recently announced that it is now releasing its generic of Pfizer’s
Dilantin tablets after receiving the FDA’s seal of approval. Dilantin is given for the
control of generalized tonic-clonic (i.e., grand mal) and complex partial (i.e.,
psychomotor, temporal lobe) seizures, and prevention and treatment of seizures occurring
during or following neurosurgery. According to IMS Health, the 50 mg chewable tablet saw
U.S. sales of close to $16.5 million for a 12 month period ending September 30, 2012. See
our technical analysis on Mylan by sign up now at

http://www.StockCall.com/MYL011813.pdf

Also in news lately has been Watson Pharmaceuticals Inc.’s [Free Analysis Report on
WPI [http://www.stockcall.com/WPI011813.pdf ]] [(1)] generic version of Ferring
Pharmaceuticals’ Lysteda tablet which received the FDA’s approval even as an infringement
lawsuit against Watson Pharma has been filed by the original maker of the drug. Whilst
this legal battle is still pending, Watson Pharma intends to make the most of the time to
launch its generic version. Last year, Lysteda saw revenues of close to $25 million in the
U.S.

Generic companies also currently have an impressive list of abbreviated new drug
applications awaiting FDA approval. Those that have first-to-file status have the
potential to be even more lucrative as these companies can enjoy a period of generic
exclusivity that is usually 180 days.

Select generic drug makers have been focusing on expansion of late, in an attempt to
grow sales and profits. Some have been acquiring competitors, while others have been
investing in growing their presence abroad. Regardless, generic drug companies appear to
be in a strong position to grow in 2013.

Footer:

        1) Watson Pharmaceuticals Inc. Technical Analysis [
          http://www.StockCall.com/WatsonPharmaceuticalsInc011813.pdf ]

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise and
comprehensive research and opinions on stocks making the headlines. Sign up today to talk
to our financial analyst at http://www.stockcall.com

SOURCE StockCall.com


Source: PR Newswire